WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF ...
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation, a global life sciences company focused on bioprocessing technologies, ...
Sartorius Stedim Biotech (SSB) said today it will integrate Repligen’s XCell™ ATF cell retention control technology into SSB’s BIOSTAT® STR large-scale single-use bioreactors to create novel perfusion ...
One-Time Therapeutics Player Bets Future on Working as Supplier to Bioprocess Companies Repligen, once a strongly focused therapeutics firm, has transformed itself into a bioprocess products company ...
Repligen reported third-quarter revenue of $24.7 million. That's better than Wall Street expected and represents a 25% year-over-year increase. CEO Tony Hunt said that this impressive growth stemmed ...
Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementation Customers experience optimized facility equipment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results